ALTAIR.

Study name	ALTAIR
Methods	Phase IV, open‐label, randomised, parallel‐group, single‐centre study
Participants	Japanese adults hospitalised for PCI and having suboptimal control of LDL‐C levels (> 70 mg/dL) despite statin therapy.
Interventions	Alirocumab 75 mg every 2 weeks added to rosuvastatin 10 mg/day Rosuvastatin 10 mg/day, with initiation or dose adjustment (or both) of non‐statin lipid‐lowering to achieve an LDL‐C target of < 70 mg/dL
Outcomes
Starting date	NA
Contact information	NA
Notes